Phase 2 obesity trial
In a phase 2, randomised, placebo-controlled, dose-ranging trial in adults with obesity, the highest dose of retatrutide tested resulted in a mean weight reduction of 24.2% at 48 weeks.
- Study type
- Human trial
- Population
- Adults with obesity (BMI 30 or above, or 27 or above with 1 or more weight-related comorbidity), without diabetes; phase 2, multi-dose, double-blind, placebo-controlled.
- Source
- 1 Jastreboff et al., 2023
Limitation: Sponsor-funded (Eli Lilly); Phase 2 dose-ranging design, not yet confirmed at Phase 3 scale in the peer-reviewed literature.
Limitations in full
Sponsor-funded (Eli Lilly); Phase 2 dose-ranging design, not yet confirmed at Phase 3 scale in the peer-reviewed literature. The larger and more widely cited TRIUMPH-1 Phase 3 result cannot be entered as corroboration per this site's source policy until it is peer-reviewed published.